Adverse Event Reporting & Safety Monitoring Flashcards
7 cards from real CRP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Adverse Event Reporting & Safety Monitoring flashcards as text
A research coordinator discovers a participant has experienced an unexpected serious adverse event. What is the FIRST priority action?
Answer: Ensure the participant receives appropriate medical care immediately
Participant safety is always the primary ethical and regulatory obligation; medical care must be arranged immediately before initiating any reporting or administrative procedures.
Emergency unblinding of a participant's treatment assignment is justified when:
Answer: Knowledge of the treatment is necessary for safe medical management of a serious adverse event
Emergency unblinding is ethically and clinically justified only when knowing the study treatment assignment is essential for making appropriate medical management decisions for the participant's safety.
Which set of information is essential to document for every adverse event in a clinical trial?
Answer: Onset date, severity grade, relationship to study product, outcome, and action taken
Complete AE documentation requires onset and resolution dates, CTCAE severity grade, causality assessment, outcome, and any changes to study participation or concomitant medications.
In clinical trial safety monitoring, 'signal detection' refers to:
Answer: Identifying potential new safety concerns by analyzing patterns across accumulating adverse event data
Signal detection involves systematic review of accumulating safety data to identify new, emerging, or changing safety patterns that may not be apparent from individual adverse event reports.
Pre-specified 'stopping rules' in a clinical trial protocol are designed to:
Answer: Halt or modify the trial if predefined safety thresholds are crossed
Stopping rules are prospectively defined safety thresholds (e.g., excess mortality, specific AE rates) that trigger mandatory trial suspension or protocol modification to protect participants.
Which agency must receive expedited adverse event reports for clinical investigations conducted under an Investigational New Drug (IND) application?
Answer: The U.S. Food and Drug Administration (FDA)
Under 21 CFR 312.32, sponsors conducting trials under an IND must submit expedited IND Safety Reports directly to the FDA.
After an IND Safety Report results in new safety information, a sponsor is typically required to update which document to reflect the new risk information?
Answer: The Investigator's Brochure (IB) with the new safety findings
When new safety information from IND Safety Reports changes the known risk profile, the Investigator's Brochure must be updated promptly so all investigators have current safety reference information.